Government Executive's research was prompted by an April 14 New York Times report on insurance companies that now require customers to pay a percentage of the full price of some drugs that treat diseases -- including anemia, hepatitis C, multiple sclerosis, rheumatoid arthritis and certain kinds of cancers -- rather than charging set co-payments that are unrelated to the drug's actual cost.